vs
Side-by-side financial comparison of WEST BANCORPORATION INC (WTBA) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
WEST BANCORPORATION INC is the larger business by last-quarter revenue ($26.9M vs $13.7M, roughly 2.0× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 39.2%, a 36.5% gap on every dollar of revenue. WEST BANCORPORATION INC produced more free cash flow last quarter ($12.4M vs $-2.1M).
West Bancorporation Inc. is a regional financial holding company headquartered in the U.S. Midwest, primarily serving markets across Iowa and Minnesota. It provides a full suite of personal and commercial banking services, including deposit accounts, mortgage loans, business lending, and wealth management solutions for individual consumers, small-to-medium enterprises, and local organizational clients.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
WTBA vs XLO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.9M | $13.7M |
| Net Profit | $10.6M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | 50.0% | -86.5% |
| Net Margin | 39.2% | 75.7% |
| Revenue YoY | 16.6% | — |
| Net Profit YoY | 34.8% | 179.1% |
| EPS (diluted) | $0.61 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $26.9M | — | ||
| Q4 25 | $24.2M | $13.7M | ||
| Q3 25 | $25.0M | $19.1M | ||
| Q2 25 | $23.8M | $8.1M | ||
| Q1 25 | $23.1M | $2.9M | ||
| Q4 24 | $20.9M | — | ||
| Q3 24 | $20.3M | — | ||
| Q2 24 | $19.6M | — |
| Q1 26 | $10.6M | — | ||
| Q4 25 | $7.4M | $10.4M | ||
| Q3 25 | $9.3M | $-16.3M | ||
| Q2 25 | $8.0M | $-15.8M | ||
| Q1 25 | $7.8M | $-13.3M | ||
| Q4 24 | $7.1M | — | ||
| Q3 24 | $6.0M | — | ||
| Q2 24 | $5.2M | — |
| Q1 26 | 50.0% | — | ||
| Q4 25 | 39.6% | -86.5% | ||
| Q3 25 | 45.8% | -10.1% | ||
| Q2 25 | 43.4% | -177.7% | ||
| Q1 25 | 43.4% | -472.7% | ||
| Q4 24 | 30.9% | — | ||
| Q3 24 | 36.6% | — | ||
| Q2 24 | 32.6% | — |
| Q1 26 | 39.2% | — | ||
| Q4 25 | 30.7% | 75.7% | ||
| Q3 25 | 37.3% | -85.4% | ||
| Q2 25 | 33.5% | -196.0% | ||
| Q1 25 | 34.0% | -452.7% | ||
| Q4 24 | 34.0% | — | ||
| Q3 24 | 29.3% | — | ||
| Q2 24 | 26.5% | — |
| Q1 26 | $0.61 | — | ||
| Q4 25 | $0.44 | $-3.74 | ||
| Q3 25 | $0.55 | $-0.11 | ||
| Q2 25 | $0.47 | $-0.16 | ||
| Q1 25 | $0.46 | $-0.18 | ||
| Q4 24 | $0.41 | — | ||
| Q3 24 | $0.35 | — | ||
| Q2 24 | $0.31 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $362.0M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $270.7M | $35.3M |
| Total Assets | $4.0B | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $362.0M | — | ||
| Q4 25 | $471.1M | $137.5M | ||
| Q3 25 | $232.9M | $103.8M | ||
| Q2 25 | $345.2M | $121.6M | ||
| Q1 25 | — | $89.1M | ||
| Q4 24 | $243.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $270.7M | — | ||
| Q4 25 | $266.0M | $35.3M | ||
| Q3 25 | $255.1M | $-8.1M | ||
| Q2 25 | $240.9M | $7.1M | ||
| Q1 25 | $237.9M | $10.7M | ||
| Q4 24 | $227.9M | — | ||
| Q3 24 | $235.4M | — | ||
| Q2 24 | $223.9M | — |
| Q1 26 | $4.0B | — | ||
| Q4 25 | $4.1B | $154.7M | ||
| Q3 25 | $4.0B | $133.7M | ||
| Q2 25 | $4.1B | $133.8M | ||
| Q1 25 | $4.0B | $103.7M | ||
| Q4 24 | $4.0B | — | ||
| Q3 24 | $4.0B | — | ||
| Q2 24 | $4.0B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $12.9M | $-2.0M |
| Free Cash FlowOCF − Capex | $12.4M | $-2.1M |
| FCF MarginFCF / Revenue | 46.0% | -15.3% |
| Capex IntensityCapex / Revenue | 1.8% | 0.7% |
| Cash ConversionOCF / Net Profit | 1.22× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $79.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $12.9M | — | ||
| Q4 25 | $46.5M | $-2.0M | ||
| Q3 25 | $11.4M | $-17.5M | ||
| Q2 25 | $13.5M | $-14.5M | ||
| Q1 25 | $9.7M | $29.0M | ||
| Q4 24 | $39.8M | — | ||
| Q3 24 | $12.9M | — | ||
| Q2 24 | $10.0M | — |
| Q1 26 | $12.4M | — | ||
| Q4 25 | $43.2M | $-2.1M | ||
| Q3 25 | $10.8M | — | ||
| Q2 25 | $12.8M | $-14.9M | ||
| Q1 25 | $8.3M | $29.0M | ||
| Q4 24 | $13.7M | — | ||
| Q3 24 | $7.0M | — | ||
| Q2 24 | $2.7M | — |
| Q1 26 | 46.0% | — | ||
| Q4 25 | 178.3% | -15.3% | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 53.6% | -184.0% | ||
| Q1 25 | 35.7% | 988.3% | ||
| Q4 24 | 65.6% | — | ||
| Q3 24 | 34.2% | — | ||
| Q2 24 | 14.0% | — |
| Q1 26 | 1.8% | — | ||
| Q4 25 | 13.7% | 0.7% | ||
| Q3 25 | 2.6% | 0.0% | ||
| Q2 25 | 3.2% | 5.0% | ||
| Q1 25 | 6.5% | 0.8% | ||
| Q4 24 | 125.3% | — | ||
| Q3 24 | 29.4% | — | ||
| Q2 24 | 37.1% | — |
| Q1 26 | 1.22× | — | ||
| Q4 25 | 6.26× | -0.19× | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 1.70× | — | ||
| Q1 25 | 1.24× | — | ||
| Q4 24 | 5.61× | — | ||
| Q3 24 | 2.17× | — | ||
| Q2 24 | 1.93× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
